Impact News +++ Ad-hoc News: CEOTRONICS AG (EQS) +++ CEOTRONICS Aktie +3,90%

THERAVANCE BIOPHARMA Aktie

>THERAVANCE BIO Aktienkurs

15 EUR (Tradegate)

Ask: 15.2 EUR / 330 Stück

Bid: 14.8 EUR / 340 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>THERAVANCE BIO Performance

1 Woche: -2,9%

1 Monat: 0%

3 Monate: +27,8%

6 Monate: +60,8%

1 Jahr: +58,2%

laufendes Jahr: +62,1%

>THERAVANCE BIOPHARMA Aktie

Name:

THERAVANCE BIOPHARMA

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG8807B1068 / A1137V

Symbol/ Ticker:

0TB (Frankfurt) / TBPH (NASDAQ)

Kürzel:

FRA:0TB, ETR:0TB, 0TB:GR, NASDAQ:TBPH

Index:

Webseite:

https://www.theravance.co..

Profil:

Theravance Biopharma Inc. is a biopharmaceutical c..
>Volltext..

Marktkapitalisierung:

763.09 Mio. EUR

Unternehmenswert:

520.23 Mio. EUR

Umsatz:

68.42 Mio. EUR

EBITDA:

-25.23 Mio. EUR

Nettogewinn:

24.99 Mio. EUR

Gewinn je Aktie:

0.49 EUR

Schulden:

37.98 Mio. EUR

Liquide Mittel:

148.87 Mio. EUR

Operativer Cashflow:

207.58 Mio. EUR

Bargeldquote:

8.81

Umsatzwachstum:

20.61%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 582.501 USD.

Suchwörter:

THERAVANCE BIOPHARMA, THERAVANCE BIO

Letzte Datenerhebung:

17.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 50.67 Mio. St.

Frei handelbar: 93.38%

Leerverk. Aktien: 11.04%

Rückkaufquote: 0.2%

Mitarbeiter: 97

Umsatz/Mitarb.: 0.57 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 44.56%

Bewertung:

KGV: 33.17

KGV lG: 9.93

KUV: 13.12

KBV: 4.06

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 93.15%

Gewinnmarge: 36.53%

Operative Marge: -43.72%

Managementeffizenz:

Gesamtkaprendite: 7.61%

Eigenkaprendite: 14.03%

>Peer Group

Es sind 101 Aktien bekannt.

>THERAVANCE BIO Chart & Kurs - NASDAQ

>THERAVANCE BIO News

10.12.25 - 19:01	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
	Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

08.12.25 - 19:45	Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? (Zacks)
	Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out....

06.12.25 - 02:01	Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 582501 USD (Insiderkauf)
	Farnum, Rhonda - Vorstand - Tag der Transaktion: 2025-12-03...

05.12.25 - 17:30	Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? (Zacks)
	The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

05.12.25 - 17:30	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

20.11.25 - 17:03	Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 (PR Newswire)
	DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD......

19.11.25 - 17:30	Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

19.11.25 - 12:03	Theravance Biopharma to Participate in Upcoming Investor Conferences (PR Newswire)
	DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside Chat Date:......

11.11.25 - 20:48	Here′s Why Shares in Theravance Biopharma Exploded Today (Fool)
	The company is making excellent progress on all its strategic goals....

11.11.25 - 01:00	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
	Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

11.11.25 - 00:01	Unerwarteter Gewinn im dritten Quartal beflügelt Aktie von Theravance Biopharma/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 22:06	Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to......

29.10.25 - 11:03	Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System (PR Newswire)
	Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN, Oct. 29, 2025 /PRNewswire/ --......

27.10.25 - 11:03	Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire)
	DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at......

14.10.25 - 12:03	Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting (PR Newswire)
	A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients Post-hoc analyses of a Phase 3......

11.09.25 - 19:00	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
	Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

02.09.25 - 12:01	Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
	DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday,......

25.08.25 - 12:03	Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy (PR Newswire)
	Topline results anticipated in Q1 2026 and, if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potential to provide durable benefit for the 40,000 patients in the U.S. with symptomatic......

13.08.25 - 01:00	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
	Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.08.25 - 22:12	Theravance Biopharma GAAP EPS of $1.08 beats by $0.41, revenue of $26.19M beats by $0.16M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram